Anticoagulation Therapy with Apixaban and Rivaroxaban

Introduction to Anticoagulation Therapy

The American College of Cardiology recommends apixaban over rivaroxaban due to its lower bleeding risk while maintaining similar effectiveness for stroke and systemic embolism prevention in patients with atrial fibrillation and valvular heart disease 1

For patients with cancer-associated thrombosis, both apixaban and rivaroxaban are recommended, but apixaban has a more favorable bleeding profile in patients with GI malignancies, while rivaroxaban has a higher GI bleeding risk 1, 2
Rivaroxaban requires dose reduction when creatinine clearance (CrCl) is between 15-30 mL/min and is not recommended when CrCl ≤15 mL/min, as per the guidelines from the European Society of Cardiology 3
Apixaban requires dose adjustment based on age, weight, and serum creatinine rather than solely on renal function, as recommended by the American Heart Association 4

For low bleeding risk procedures, the last dose of apixaban or rivaroxaban should be taken the day before the procedure, as suggested by the American Society of Anesthesiologists 5
For high bleeding risk procedures, both apixaban and rivaroxaban should be interrupted 3 days before the procedure, according to the guidelines from the American College of Chest Physicians 5
For very high bleeding risk procedures (e.g., neurosurgery), longer interruption times are recommended by the Neurocritical Care Society 5

For patients with GI or genitourinary malignancies, apixaban is strongly preferred over rivaroxaban due to its lower bleeding risk, as recommended by the National Comprehensive Cancer Network 1, 2
For patients with renal impairment, apixaban may be preferred with appropriate dose adjustment, as suggested by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 4
The European Society of Cardiology recommends monitoring renal function to adjust dosing and minimize bleeding risk, particularly with rivaroxaban 3

Both apixaban and rivaroxaban interact with P-glycoprotein inhibitors, but rivaroxaban is also affected by CYP3A4 inhibitors, creating more potential drug interaction scenarios, as warned by the FDA 1
Apixaban is dosed twice daily, while rivaroxaban is once daily for most indications (except initial VTE treatment), as stated by the manufacturer's instructions 4